Xanthomatosis

Download PDF

Recent Publications on Xanthomatosis:
[Perifollicular xanthomatosis as a key histological finding in Fox-Fordyce disease] Fox-Fordyce disease is a rare skin condition characterized by the presence...	17th July, 2008	Servicio de Dermatologia, Hospital General Universitario de Alicante,	Actas Dermosifiliogr. 2008 Mar;99(2):145-8.
Teaching neuroimage: cerebrotendinous xanthomatosis. Glucose oxidase, horseradish peroxidase, xanthine oxidase, and carbonic...	9th July, 2008	Department of Neurology, Massachusetts General Hospital, Brigham and	Neurology. 2008 Jul 8;71(2):e4. DOI Direct Link
Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. Background and purpose:Inhibition of squalene synthesis could transform...	1st July, 2008	1Institute for Experimental Animals, Kobe University School of Medicine,	Br J Pharmacol. 2008 Jul;154(5):949-57. Epub 2008 Apr 21. DOI Direct Link
Xanthogranulomatous inflammation of the small bowel in a dog. A case of xanthogranulomatous inflammation of the small bowel in a...	27th June, 2008	Department of Comparative Biomedical Sciences, Faculty of Veterinary	Vet Pathol. 2008 Mar;45(2):207-11. DOI Direct Link
Mechanisms of Disease: inborn errors of bile acid synthesis. Inborn errors of bile acid synthesis are rare genetic disorders that can...	26th June, 2008	SS Sundaram is an Assistant Professor of Pediatrics in the Section of	Nat Clin Pract Gastroenterol Hepatol. 2008 Jun 24;. DOI Direct Link
→View more research publications.

BioNews Results for Xanthomatosis:
Sigma-Tau acquires Chenofalk from Germany-based Dr Falk Pharma	PharmaBiz:  Jul 12 2008 10:33AM Matching: xanthomatosis
Sigma-Tau Pharmaceuticals seeking FDA approval of medicine for rare genetic disease affecting less than 100 Am	Checkbiotech:  Jul 10 2008 12:06PM Matching: xanthomatosis
Sigma-Tau Pharmaceuticals Seeking FDA Approval of Medicine for Rare Genetic Disease Affecting Less Than 100 Am	Genetic Engineering News:  Jul 9 2008 6:52PM Matching: xanthomatosis
Sigma-Tau Pharmaceuticals Seeking FDA Approval of Medicine for Rare Genetic Disease Affecting Less Than 100 Am	Street Insider:  Jul 9 2008 6:51PM Matching: xanthomatosis
Sigma-Tau Pharmaceuticals Seeking FDA Approval of Medicine for Rare Genetic Disease Affecting Less Than 100 Am	Houston Chronicle:  Jul 9 2008 6:32PM Matching: xanthomatosis
Promote your company here: BioNewsCast - Press Release Distribution	→View more news.

Xanthomatosis Clinical Trials:
Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis	Cerebrotendinous Xanthomatosis

Xanthomatosis Patents:
US Patent No.	Title
6974667	Gene expression profiles in liver cancer
7112426	Human cAMP-dependent protein kinase beta-catalytic subunit
7119221	Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
7122345	Nucleic acid encoding a NOVX13 polypeptide
7132415	Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Xanthomatosis scientists - we have details of around 372 individuals working on Xanthomatosis .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.